2010/06/07

TRIMETAZIDE

Pharmacological action

Antianginal drug that improves myocardial metabolism. Has antihypoxia, hypotensive and koronarodilatiruyuschee action.

Immediately improves the metabolism of cardiomyocytes and neurons of the brain. Cytoprotective effect explained by rising energy potential, activation of oxidative decarboxylation and the rationalization of consumption of oxygen through increased aerobic glycolysis and inhibition of oxidation of fatty acids. Supports normal myocardial contractility, prevents the depletion of intracellular ATP and fosfokreatinina. In a state of acidosis normalizes membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate levels, due to myocardial ischemia and reperfusion. It prevents the damaging action of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic area, reduces the yield of CK from the cells and the severity of ischemic myocardial damage.

When angina reduces the frequency of attacks. After 2 weeks of treatment increased exercise tolerance, reduced blood pressure drops. Against the background of the drug improves the results of hearing and vestibular tests, reduces dizziness and tinnitus. In the eyes of vascular pathology improves functional status of the retina.


Pharmacokinetics

Absorption

Once inside quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability is 90%. After a single oral dose of 20 mg of C max achieved after 2 h and is approximately 55 ng / ml.

Distribution

Easily penetrates through histohematogenous barriers. Plasma protein binding is 16%.

Withdrawal

We derive the kidneys, about 60% - unchanged. T 1 / 2 - 4.5-5 hours


Statement

- Coronary heart disease, angina (in the complex therapy);

- Chorioretinal circulatory disorders with ischemic component;

- Dizziness of vascular origin;

- Treatment of vestibular disorders kohleo-ischemic nature (tinnitus, hearing loss).


Dosage regimen

Trimetazid prescribe oral dose of 60 mg / day in 2-3 reception. Duration of treatment set individually.

Tablets are taken with food.


Side effect

On the part of the digestive system: rarely - epigastric pain, nausea, vomiting.

Allergic reactions: itching.

Other: headache, feeling of palpitations.


Contraindications

- Renal insufficiency (CC <15 ml / min);

- Marked disturbances of liver function;

- Childhood and adolescence to 18 years;

- Pregnancy

- Lactation (breastfeeding);

- Hypersensitivity to the drug.


Application of pregnancy and breastfeeding

Trimetazid contraindicated during pregnancy and lactation.


Application for violations of liver function

Contraindications disturbancies liver function.


Application for violations of renal function

Contraindicated in renal insufficiency (CC <15 ml / min).


Cautions

Against the background of the drug in patients with coronary heart disease significantly reduced the daily need for nitrates.

Effects on ability to drive vehicles and management mechanisms

Trimetazid not affect the ability to drive a car and perform work requiring a high speed of psychomotor reactions.


Overdose

Currently, cases of overdosing Trimetazid not reported.


Drug Interactions

Drug Interactions drug Trimetazid not described.


To the top

Drug prescription.


Terms and Conditions of storage

List B. The drug should be stored protected from moisture and away from children at or above 25 ° C. Shelf life - 3 years.